It’s time to beat cancer

Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.

Find Out More

We are building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). We believe that by reprogramming the TIME, we can significantly improve cancer treatment outcomes.


Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis via CD36 and CD47 pathways.

Learn More

OUR <strong>APPROACH</strong>

Our clinical

We are currently studying VT1021, a peptide therapeutic agent in clinical trials enrolling patients in pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high amounts of CD36.

Working at

Find out more about a career at Vigeo


Latest News

July 13, 2023

Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient

Read More »

June 02, 2023

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

Read More »

May 25, 2023

Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients

Read More »